Published in AIDS Weekly, May 24th, 2004
Immunovirological "outcomes and toxicities of HAART regimens, including Lopinavir (LPV)/ritonavir (r) and indinavir (IDV)/r," were compared in antiretroviral naive HIV-1 patients. Fifty-five and 52 patients, respectively, were selected to start LPV/r or IDV/r as first-line HAART, according to research in Italy.
"Immunovirological and metabolic parameters were recorded at baseline and every 3 months as were side effects, AIDS-defining events and deaths. Demographic characteristics and NRTIs included in the regimens were comparable," wrote M....
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.